<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984425</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-2008-005</org_study_id>
    <nct_id>NCT00984425</nct_id>
  </id_info>
  <brief_title>The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors</brief_title>
  <official_title>Phase I and Pharmacokinetics Study of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over the last decade, improvements in the investigators' understanding of the molecular basis
      of cancer have led to the clinical development of protein kinase inhibitors, which target
      pivotal molecules involved in intracellular signaling pathways implicated in tumorigenesis
      and tumor progression. Lapatinib is an oral selective and reversible inhibitor of the
      tyrosine kinase domain of epidermal growth factor receptor (EGFR) and human epidermal growth
      factor receptor type 2 (HER-2), which are both frequently altered in human malignant tumors.
      Sorafenib is an oral multi-kinase inhibitor with a dual-action that prevents tumor cell
      proliferation and angiogenesis. The investigators suggest that through a complete blockade of
      ErbB signaling network it may be possible to ''sensitize'' tumor cells to antiangiogenic
      therapy, by lowering the tumor cell survival threshold, while through inhibition of vascular
      endothelial growth factor (VEGF) pathway to circumvent the problem of acquired resistance to
      EGFR inhibitors. Based on this theoretical rationale we decide to test the combination of
      Lapatinib and Sorafenib. This phase I trial will be undertaken to assess the maximum dose
      tolerated (MTD), safety/tolerability, pharmacokinetics and antitumor efficacy of this
      combination in patients with advanced, recurrent or metastatic solid cancers refractory to
      available standard treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dual-agent, prospective, open-label, multi-centric, phase I trial of combination of
      Lapatinib and Sorafenib in patients with locally advanced, recurrent or metastatic solid
      tumors. This trial will be conducted to determine the maximum tolerated dose (MTD),
      safety/tolerability, pharmacokinetics, and antitumor activity of these two agents given
      together on a continuous schedule, in patients with advanced solid tumors.

      Our ambition is to recommend a safe dose regimen of the combination for subsequent larger
      phase II studies, coinciding with the maximum tolerated dose (MTD).

      The maximum tolerated dose (MTD), will be defined as the highest dosage cohort at which no
      more than one of six patients will be experienced a DLT in the first treatment cycle.

      Eligible patients will be enrolled and treated according to the schema, using a 3+3 design
      (Fibonacci method modified);
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the dose limiting toxicities (DLTs)and the maximum tolerated dose (MTD) of the combination of Lapatinib and Sorafenib.</measure>
    <time_frame>0ne year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the safety profile of escalating doses of Lapatinib in combination with escalating doses of Sorafenib and and to compare the pharmacokinetics of Lapatinib alone and in combination with Sorafenib</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Lapatinib and Sorafenib 1° level of dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lapatinib 750 mg/die + Sorafenib 200 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lapatinib and Sorafenib 2° level of dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2° level (II cohort): Lapatinib 1000 mg/die + Sorafenib 200 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lapatinib and Sorafenib 3° level of dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3° level (III cohort): Lapatinib 1000 mg/die + Sorafenib 400 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lapatinib and Sorafenib 4° level of dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4° level (IV cohort): Lapatinib 1250 mg/die + Sorafenib 400 mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib and Sorafenib</intervention_name>
    <description>Comparison of different dosages of two drug</description>
    <arm_group_label>Lapatinib and Sorafenib 1° level of dose</arm_group_label>
    <arm_group_label>Lapatinib and Sorafenib 2° level of dose</arm_group_label>
    <arm_group_label>Lapatinib and Sorafenib 3° level of dose</arm_group_label>
    <arm_group_label>Lapatinib and Sorafenib 4° level of dose</arm_group_label>
    <other_name>Tykerb and Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with locally advanced, recurrent or metastatic histologically confirmed
             malignancy refractory to available standard treatment

        Exclusion Criteria:

          -  Prior treatment with Lapatinib, Sorafenib or any agents targeting EGFR (other than
             trastuzumab), Raf, VEGF, or VEGFR
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Santoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinco Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Simonelli M, Zucali PA, Lorenzi E, Rubino L, De Vincenzo F, De Sanctis R, Perrino M, Mancini L, Di Tommaso L, Rimassa L, Masci G, Zuradelli M, Suter MB, Bertossi M, Fattuzzo G, Giordano L, Roncalli MG, Santoro A. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. Eur J Cancer. 2013 Mar;49(5):989-98. doi: 10.1016/j.ejca.2012.10.016. Epub 2012 Nov 9.</citation>
    <PMID>23146956</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2009</study_first_submitted>
  <study_first_submitted_qc>September 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2009</study_first_posted>
  <last_update_submitted>November 26, 2014</last_update_submitted>
  <last_update_submitted_qc>November 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

